Allena Pharmaceuticals, Inc. EPS (Diluted)

EPS (Diluted) of ALNA for past 10 years: annual, quarterly and twelve month trailing (TTM) including EPS (Diluted) growth rates and interactive chart. Diluted earnings per share (EPS) tells investors how much of a firm's net income was allotted to each share of common stock. It is reported in a company's income statement and is especially informative for businesses with only common stock in their capital structures. Calculated as net income to common divided by the weighted average number of diluted shares outstanding (takes into account potential dilution from options or share issuance).


Highlights and Quick Summary

  • EPS (Diluted) for the quarter ending September 30, 2021 was -0.17 (a -29.17% decrease compared to previous quarter)
  • Year-over-year quarterly EPS (Diluted) decreased by -29.17%
  • Annual EPS (Diluted) for 2020 was -1.01 (a -52.58% decrease from previous year)
  • Annual EPS (Diluted) for 2019 was -2.13 (a 23.84% increase from previous year)
  • Annual EPS (Diluted) for 2018 was -1.72 (a -64.17% decrease from previous year)
Visit stockrow.com/ALNA for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical EPS (Diluted) of Allena Pharmaceuticals, Inc.

Most recent EPS (Diluted)of ALNA including historical data for past 10 years.

Interactive Chart of EPS (Diluted) of Allena Pharmaceuticals, Inc.

Allena Pharmaceuticals, Inc. EPS (Diluted) for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2021 -0.17 -0.24 -0.21
2020 -0.24 -0.22 -0.26 -0.31 -1.01
2019 -0.47 -0.57 -0.54 -0.55 -2.13
2018 -0.46 -0.46 -0.42 -0.38 -1.72
2017 -0.48 -3.49 -4.8
2016 -1.15

Business Profile of Allena Pharmaceuticals, Inc.

Sector: Healthcare
Industry: Biotechnology
Allena Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States. Its lead product candidate is ALLN-346, a novel and urate degrading enzyme for patients with hyperuricemia and gout in the setting of advanced chronic kidney disease. The company was incorporated in 2011 and is headquartered in Newton, Massachusetts.